Ozempic's nearly $14 billion sales in 2023 has made it a phenomenon, with the Danish manufacturer, Novo Nordisk, reaping significant profits from this unintended side-effect.
Founded in 1923, Novo Nordisk has evolved from creating insulin to becoming a pharmaceutical giant, yet its practices have raised regulatory red flags internationally.
Novo Nordisk faces scrutiny with ongoing investigations into its pricing strategies for Ozempic and Wegovy, with prices in the US significantly higher than in Europe.
Despite past regulatory challenges and lawsuits, investors focus on the long-term stock performance of Novo Nordisk, emphasizing the unpredictability of pharmaceutical market projections.
Collection
[
|
...
]